Lyxia key facts
as of Oct 2026- Manufacturer of microalgae-derived nutritional ingredients intended for human and animal health through targeted lipid and bioactive compound development.
- Lyxia is valued at approximately $57.0M as of Oct 2026 (last reported valuation).
- It has raised $34.1M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Oriental Fortune Capital, Decent Capital, Guofu Innovation, Fanqie Capital, Hatchip Capital — 12 tracked in total.
- Status: Privately Held (backing).
Lyxia's last reported valuation, Sep 2014. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Lyxia: the Monday email on marks, rounds and moves
Lyxia funding rounds
No funding rounds for Lyxia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Lyxia
12+Lyxia valuation
Lyxia's last reported valuation was $57 million in Sep 2014. No priced round, secondary trade or fund mark has surfaced since.
Lyxia investors
12 investors are on record for Lyxia, including Oriental Fortune Capital, Decent Capital, Guofu Innovation and Fanqie Capital.
About Lyxia
Manufacturer of microalgae-derived nutritional ingredients intended for human and animal health through targeted lipid and bioactive compound development. The company offers vertically integrated cultivation, environmentally aligned production methods, and specialized extraction techniques that preserve the characteristics of sensitive components, enabling nutrition, health, and wellness industries to incorporate stable and traceable quality.
- Sector
- Materials and Resources
- HQ
- Huzhou, China
- Founded
- 2012
- Employees
- 130
- Website
- xiaozaotech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.